Who
Todd C. Brady
President and CEO
Company insider
Files Form 4 as: President and CEO, Aldeyra Therapeutics; Director, Evoke Pharma; Director, F-star Therapeutics; Director, Outlook Therapeutics.
In numbers
- Trades disclosed
- 106
- Buys
- 15
- Sells
- 2
- Bought
- $1.7M
- Sold
- $580K
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 24 Sep 2013
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Bought | $418K250,000 at $1.67 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Bought | $418K250,000 at $1.67 | filing |
| 27 Mar 2026filed 31 Mar 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,880,510 at $0.00 | filing |
| 27 Mar 2026filed 31 Mar 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —632,318 at $0.00 | filing |
| 27 Mar 2026filed 31 Mar 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,880,510 at $0.00 | filing |
| 27 Mar 2026filed 31 Mar 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —632,318 at $0.00 | filing |
| 17 Dec 2025filed 17 Dec 2025 | Evoke Pharmaoption or derivative | SEC FORM 4 Code D | —1,218 | filing |
| 17 Dec 2025filed 17 Dec 2025 | Evoke Pharmaoption or derivative | SEC FORM 4 Code D | —5,833 | filing |
| 17 Dec 2025filed 17 Dec 2025 | Evoke Pharmaoption or derivative | SEC FORM 4 Code D | —1,187 | filing |
| 16 Dec 2025filed 17 Dec 2025 | Evoke Pharma | SEC FORM 4 Code U | —27 | filing |
| 21 May 2025filed 22 May 2025 | Evoke Pharmaoption or derivative | SEC FORM 4 Code A | —1,187 at $0.00 | filing |
| 4 Mar 2025filed 6 Mar 2025 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —809,710 at $0.00 | filing |
| 28 Jan 2025filed 29 Jan 2025 | Evoke Pharmaoption or derivative | SEC FORM 4 Code A | —5,833 at $0.00 | filing |
| 22 May 2024filed 24 May 2024 | Evoke Pharmaoption or derivative | SEC FORM 4 Code A | —14,625 at $0.00 | filing |
| 12 Mar 2024filed 12 Mar 2024 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Sold | $260K85,324 at $3.05 | filing |
| 11 Mar 2024filed 12 Mar 2024 | ALDX Aldeyra TherapeuticsBiotechnology | SEC FORM 4 Sold | $320K97,914 at $3.27 | filing |
| 9 Mar 2024filed 12 Mar 2024 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,081,201 at $0.00 | filing |
| 7 Sep 2023filed 11 Sep 2023 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —192,084 at $0.00 | filing |
| 7 Sep 2023filed 11 Sep 2023 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —32,953 at $0.00 | filing |
| 7 Sep 2023filed 11 Sep 2023 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —48,021 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.